31st week of 2019 patent applcation highlights part 26 |
Patent application number | Title | Published |
20190233352 | PROCESS FOR PRODUCING A CHLORINATED C3-6 ALKANE - Disclosed is a process for producing a chlorinated C3-6 alkane comprising providing a reaction mixture comprising an alkene and carbon tetrachloride in a principal alkylation zone to produce chlorinated C3-6 alkane in the reaction mixture, and extracting a portion of the reaction mixture from the principal alkylation zone, wherein:
| 2019-08-01 |
20190233353 | PROCESS FOR PRODUCING HALOGENATED OLEFINS - Disclosed herein is a process comprising contacting a haloalkane reactant with an olefin in the presence of a catalyst system that consists of metallic iron and a phosphine to produce a haloalkane insertion product, wherein said haloalkane reactant is an alkane substituted with at least one halogen selected from the group consisting of F, Cl, and combinations thereof. Also disclosed herein is a process comprising contacting CF | 2019-08-01 |
20190233354 | EFFICIENT DISTILLATION OF ETHANOL - Systems and methods in accordance with the present invention provide for the efficient distillation of ethanol in an ethanol plant including a beer column. Heat is captured in the distillation process and utilized to drive operations in the ethanol plant. | 2019-08-01 |
20190233355 | SYSTEMS AND METHODS FOR MAKING ETHANOL PRODUCTS - A method for producing an ethanol product includes obtaining a condensed distillate including ethanol at a concentration greater than 30% by volume and contacting the condensed distillate with an adsorbent polymer resin. The adsorbent polymer resin includes a polystyrene divinylbenzene copolymer. A surface of the adsorbent polymer resin is hydrophobic. | 2019-08-01 |
20190233356 | SYSTEM AND PROCESS FOR REMOVAL OF ORGANIC CARBOXYLATES FROM MONO ETHYLENE GLYCOL (MEG) WATER STREAMS BY ACIDIFICATION AND VAPORATION UNDER VACUUM - A system and method for removing organic carboxylates from a mono ethylene glycol (“MEG”) stream includes a reaction vessel; means for cooling and diluting the MEG stream being routed to the reaction vessel; means for acidifying the cooled and diluted MEG stream during its residence time within the reaction vessel; and means for removing an acetic-rich overhead stream from the reaction vessel. The acidification of the cooled and diluted MEG stream occurs under a vacuum. The reaction vessel may be located downstream of a calcium removal vessel and receive a filtered bottom stream from that vessel, or it may be a single reaction vessel that cycles between a calcium removal mode and an acetate removal mode, with the pressure of the single vessel being greater during the calcium removal mode than during the acetate removal mode. | 2019-08-01 |
20190233357 | 6-ISOPROPYL-2,4-DIMETHYLCYCLOHEXEN-1-OL COMPOUNDS AS FRAGRANCE INGREDIENTS - The present invention refers to 6-isopropyl-2,4-dimethylcyclohexen-1-ol derivatives, to a method of their production, and fragrance compositions and fragranced articles comprising them. | 2019-08-01 |
20190233358 | MATERIALS COATED WITH CALIXARENES - This invention relates to the direct grafting of a calixarene mostly onto the surface of a material, as well as to a grafting process, and certain calixarene intermediates useful for carrying the grafting process. | 2019-08-01 |
20190233359 | Series of Skin Whitening (Lightening) Compounds - The present invention is directed to inhibitors of tyrosinase, pharmaceutical compositions comprising such tyrosinase inhibitors, and methods of making and using the same. Specifically, included in the present invention are compositions of matter comprised of at least one 2,4-dihydroxybenzene analog, which inhibit the activity of tyrosinase and which inhibit the overproduction of melanin. | 2019-08-01 |
20190233360 | Methods for Production of Aromatic Dicarboxylic Acids and Derivatives Thereof - Provided are methods for the production of phthalic acid (PA), isophthalic acid (IP A), terephthalic acid (TP A), and derivatives thereof. The methods are based on the addition of beta propiolactone to furfural or a derivative thereof. Provided are cost effective routes to biobased IP A and derivatives thereof, including terephthalic acid. | 2019-08-01 |
20190233361 | METHOD FOR PRODUCING HIGH-PURITY TEREPHTHALIC ACID - A method for producing high-purity terephthalic acid, comprising following steps (a) to (e): | 2019-08-01 |
20190233362 | SYNTHESIS OF INTERMEDIATES FOR PRODUCING PROSTACYCLIN DERIVATIVES - The present disclosure provides regioselective methods for synthesizing intermediates useful in making prostacyclin derivatives, such as treprostinil. | 2019-08-01 |
20190233363 | SURFACE ACTIVE IONIC LIQUID WITH ACTIVITY IN AQUEOUS AND NON-AQUEOUS MEDIA - Disclosed herein are surfactant compounds, that are surface active, liquid, chiral, and micelle forming. Also disclose herein are ionic liquids and compsitions comprising the surfactant compounds. | 2019-08-01 |
20190233364 | CATALYST MODIFICATION WITH ALKALI METAL, ALKALINE EARTH METAL OR RARE EARTH METAL IONS IN THE CONTINUOUS LIQUID-PHASE HYDROGENATION OF NITRO COMPOUNDS - The present invention relates to a process for continuous hydrogenation of a nitro compound to the corresponding amine in a liquid reaction mixture comprising the nitro compound in the presence of a supported catalyst which comprises as the active component at least one element from groups 7 to 12 of the periodic table of the elements, wherein the hydrogenation is performed in the presence of at least one salt selected from the group consisting of the salts of the alkali metals, alkaline earth metals and of the rare earth metals and to a supported catalyst for continuous hydrogenation of a nitro compound to the corresponding amine in a liquid reaction mixture comprising the nitro compound which comprises as the active component at least one element from groups 7 to 12 of the periodic table of the elements and one salt of the alkali metals, alkaline earth metals or of the rare earth metals. | 2019-08-01 |
20190233365 | METHOD FOR PRODUCING ANILINE OR AN ANILINE CONVERSION PRODUCT - The invention relates to a method for producing aniline or products that are obtained by further chemical reaction of aniline (aniline derivatives), involving decarboxylation of aminobenzoic acid, particularly ortho-aminobenzoic acid, in which one portion of the previously formed crude aniline is recirculated in the decarboxylation step. The aminobenzoic acid is obtained enzymatically or chemically, preferably enzymatically. | 2019-08-01 |
20190233366 | CRYSTALLINE DIETHYLAMINE TETRATHIOMOLYBDATE AND ITS PHARMACEUTICAL USES - The invention relates to a crystalline diethylamine tetrathiomolybdate salt (DEA-TTM). The invention also relates to methods for producing the crystalline DEA-TTM salt of the invention. The invention also relates to pharmaceutical compositions comprising the crystalline DEA-TTM salt of the invention. The invention also relates to the use of the crystalline DEA-TTM salt of the invention in the treatment of the human or animal body, in particular its use in treatment of a condition requiring reduced metabolism of an organ or the whole body of a patient, by administering to a patient in need thereof a therapeutically effective amount of the crystalline DEA-TTM salt. | 2019-08-01 |
20190233367 | HIGH PENETRATION PRODRUG COMPOSITIONS OF MUSTARDS AND MUSTARD-RELATED COMPOUNDS - The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of mustards and mustard-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate. | 2019-08-01 |
20190233368 | METHOD FOR PRODUCING FLUORINE-CONTAINING SULFONYLAMIDE COMPOUND - A method for efficiently removing impurities such as sodium ions, fluoride ions, chloride ions and fluorosulfate ions without reducing the yield of a target product, including a fluorine-containing sulfonylamide compound selected from the group consisting of fluorine-containing sulfonylamide, a metal salt thereof, an ammonium salt thereof and a quaternary ammonium salt thereof is washed with an aqueous solution of salt of sulfuric acid. | 2019-08-01 |
20190233369 | USE OF ACYLSULFONAMIDES FOR IMPROVING PLANT YIELD - Compounds (A) can be used for increasing the yield of useful plants or crop plants with respect to their harvested plant organs, wherein the Compound (A) is selected from compounds of the formula (I) or salts thereof, | 2019-08-01 |
20190233370 | CYCLIC COMPOUND - The present invention provides a compound having a superior Toll-like receptor 4 (TLR4) signaling inhibitory action, which may be useful as a prophylactic or therapeutic drug for diseases such as autoimmune diseases and/or inflammatory diseases, or chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver failure, and ischemia reperfusion injury (IRI). | 2019-08-01 |
20190233371 | Isothiocyanate Production Method, Composition for Transporting and Storing N-Substituted O-Substituted Thiocarbamate, and Isothiocyanate Composition - The present invention relates to an isothiocyanate production method using an organic primary amine and thiourea as starting materials; to a composition for transporting and storing an N-substituted O-substituted thiocarbamate that includes an N-substituted O-substituted thiocarbamate and a hydroxy compound, the equivalent weight ratio of hydroxy groups of the hydroxy compound with respect to the carbamate groups of the N-substituted O-substituted thiocarbamate being in the range of 1 to 100; to a composition for transporting and storing a compound with a thioureido group that includes a compound with a thioureido group and a hydroxy compound, the equivalent weight ratio of hydroxy groups of the hydroxy compound with respect to the thioureido groups of the compound with a thioureido group being in the range of 1 to 100; and to an isothiocyanate composition containing an isothiocyanate and a compound with a specific functional group. | 2019-08-01 |
20190233372 | Carbondisulfide Derived Zwitterions - Amines and amine derivatives that improve the buffering range, and/or reduce the chelation and other negative interactions of the buffer and the system to be buffered. The reaction of amines or polyamines with various molecules to form polyamines with differing pKa's will extend the buffering range, derivatives that result in polyamines that have the same pKa yields a greater buffering capacity. Derivatives that result in zwitterionic buffers improve yield by allowing a greater range of stability. | 2019-08-01 |
20190233373 | Cyclic Imide Slurry Compositions - Provided herein is a cyclic imide slurry composition and processes for forming and/or using such a composition. The slurry composition comprises solid cyclic imide and organic liquid, such as liquid alkylbenzene, liquid cyclohexane, and/or liquid organic alcohol (such as cyclohexanol). The slurry composition may find particular use in processes in which the cyclic imide serves as an oxidation catalyst (e.g., as a radical initiator). For instance, the slurry composition may be useful in the oxidation of a liquid alkylbenzene such as cyclohexylbenzene to corresponding 1-cyclohexyl-1-phenyl hydroperoxide. Such an oxidation reaction may further be part of an integrated process for the production of phenol and/or cyclohexanone from benzene via hydroalkylation to form cyclohexylbenzene. | 2019-08-01 |
20190233374 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS - There are described ROR | 2019-08-01 |
20190233375 | SYNTHESIS OF INHIBITORS OF EZH2 - Provided herein are synthetic methods for the preparation of EZH2 inhibitors. | 2019-08-01 |
20190233376 | GUANIDINE DERIVATIVE AND MEDICAL USE THEREOF - A compound has a guanidine skeleton that inhibits the protease activity of MALT1 and exerts a therapeutic or prophylactic effect on autoimmune disease such as psoriasis or allergic disease such as atopic dermatitis. The guanidine derivative is typified by the following formula or a pharmacologically acceptable salt thereof. | 2019-08-01 |
20190233377 | BICYCLIC COMPOUNDS - Disclosed herein are compounds of Formulae (I) and (II), methods of synthesizing compounds of Formulae (I) and (II), and methods of using compounds of Formulae (I) and (II) as an analgesic. | 2019-08-01 |
20190233378 | METHOD FOR THE PURIFICATION OF ETHOXYQUIN - The present invention relates to a process for purifying ethoxyquin by distillation, to high-purity ethoxyquin obtainable by means of distillative purification and to the use thereof, particularly as additive in foodstuffs and feedstuffs. | 2019-08-01 |
20190233379 | IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS - The invention provides novel compounds having the general formula (I) | 2019-08-01 |
20190233380 | FLUOROALKYLATING AGENT - Problem to be Solved | 2019-08-01 |
20190233381 | METHOD FOR PREPARING URATE TRANSPORTER 1 INHIBITOR - Provided is a method for preparing a URAT1 inhibitor, 2-((5-bromo-4-((4-bromonaphthalen-1-yl)methyl)-4H-1,2,4-triazol-3-yl)thio) acetic acid represented by the following formula ZXS-BR, the reaction equation of which being shown as follows. Compared with the prior art, the preparation method provided by the present application is of low cost, ease of handling, ease of quality control, and applicable to industrialization. | 2019-08-01 |
20190233382 | METHOD FOR PRODUCING 3-ALKYLSULFANYL-2-CHLORO-N-(1-ALKYL-1H-TETRAZOL-5-YL)-4-TRIFLUOROMETHYL-B- ENZAMIDES - The invention relates to a method for producing 3-alkylsulfanyl-2-chloro-N-(1-alkyl-1H-tetrazol-5-yl)-4-trifluoromethyl-benzamides of formula (I). In said formula, the substituents R | 2019-08-01 |
20190233383 | THIAZOLE INNER SALT COMPOUNDS, AND PREPARATION METHODS AND USES THEREOF - The present invention pertains to field of pharmaceutical chemicals, and relates to thiazole inner salt compounds, preparation methods and uses thereof. Specifically, the present invention relates to a compound of Formula I, hydrates or pharmaceutically acceptable salts thereof. The compound of Formula I of the present invention is a potent cross-linking protein cleavage agent, has a stable structure, good physical and chemical properties, and good pharmacological activities, and is suitable for large scale production to obtain samples with stable, controllable and reliable quality, thereby being suitable for pharmaceutical development. | 2019-08-01 |
20190233384 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF - The present invention relates to heterocyclic compounds of Formula I useful as anti-infective agents. The present invention further relates to a method of treating an infection by administering such compounds, and to pharmaceutical compositions comprising such compounds. | 2019-08-01 |
20190233385 | ELECTRONICALLY ACTIVATED STRAINED ALKYNES - Compounds of Formula I: | 2019-08-01 |
20190233386 | PROCESSES FOR THE PREPARATION OF 2,5-FURANDICARBOXYLIC ACID AND INTERMEDIATES AND DERIVATIVES THEREOF - The present disclosure provides processes for the production of 2-5-furandicarboxylic acid (FDCA) and intermediates thereof by the chemocatalytic conversion of a furanic oxidation substrate. The present disclosure further provides processes for preparing derivatives of FDCA and FDCA-based polymers. In addition, the present disclosure provides crystalline preparations of FDCA, as well as processes for making the same. | 2019-08-01 |
20190233387 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME - Described herein are Δ | 2019-08-01 |
20190233388 | ELECTROLYTE FOR HIGH VOLTAGE LITHIUM-ION BATTERIES - An electrolyte, electrochemical device, battery, capacitor, and/or the like include a salt; and a fluorinated organosulfate compound represented by Formula I: | 2019-08-01 |
20190233389 | PROCESS FOR THE PREPARATION OF POMALIDOMIDE AND ITS PURIFICATION - The present invention is related to an improved process for the preparation of Pomalidomide with higher yields and high purity. Particularly the present invention relates to form A preparation of Pomalidomide and its purification, wherein the present process doesn't involve use of dioxane solvent and avoids higher temperatures. | 2019-08-01 |
20190233390 | NOVEL PIPERIDINE CARBOXAMIDE COMPOUND, PREPARATION METHOD, AND USE THEREOF - The present invention provides a compound of a general formula I, a stereomeride, pharmaceutically acceptable salt or a solvate thereof, a preparation method thereof, and usages in preparing medicines for preventing and/or treating diseases or symptoms caused by drug-resistant tumors or drug-resistant bacteria and in preparing medicines for preventing and/or treating diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection. Preferably, the diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection are diseases or symptoms caused by a heat shock protein 70 (Hsp70). The compound in the present invention is used for overcoming a difficult problem of drug resistance of tumors, improves the effect of tumor treatment, and provides a new medical strategy for clinical tumor treatment. | 2019-08-01 |
20190233391 | Benzodiazepine Derivatives As CCK2/Gastrin Receptor Antagonists - The invention relates to benzodiazepine derivatives of formula (A) useful as CCK | 2019-08-01 |
20190233392 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR - This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases. | 2019-08-01 |
20190233393 | CRYSTALLINE FORM OF RECEPTOR AGONIST, AND MANUFACTURING METHOD AND PHARMACEUTICAL COMPOSITION THEREOF - The present invention relates to the crystalline forms of a 5-HT | 2019-08-01 |
20190233394 | PHARMACEUTICAL COMPOUNDS - The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy. | 2019-08-01 |
20190233395 | SUBSTITUTED INDAZOLES, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAID NEW SUBSTITUTED INDAZOLES, AND USE OF SAID NEW SUBSTITUTED INDAZOLES TO PRODUCE DRUGS - The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis. | 2019-08-01 |
20190233396 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF - Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 2019-08-01 |
20190233397 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF - Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of certain chemokine receptor activity. | 2019-08-01 |
20190233398 | HETEROCYCLIC COMPOUND, AND ORGANIC LIGHT-EMITTING DEVICE USING SAME - The present application provides a hetero-cyclic compound capable of significantly enhancing lifespan, efficiency, electrochemical stability and thermal stability of an organic light emitting device, and an organic light emitting device containing the hetero-cyclic compound in an organic compound layer. | 2019-08-01 |
20190233399 | PHARMACEUTICAL SALTS N-(2-(2-(DIMETHYLAMINO)ETHOXY)-4-METHOXY-5-((4-(1-METHYL-1H-INDOL-3-YL)PY- RIMIDIN-2-YL)AMINO)PHENYL)ACRYLAMIDE AND CRYSTALLINE FORMS THEREOF - Crystalline forms of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide (1) and its pharmaceutically acceptable salts and compositions thereof useful for the treatment or prevention of diseases or medical conditions mediated through mutated forms of epidermal growth factor receptor (EGFR), such as various cancers, are disclosed. | 2019-08-01 |
20190233400 | Crystalline Form of Olaparib - The present invention provides a novel crystalline form of Olaparib comprising Olaparib and benzyl alcohol, compositions thereof, and the use of this crystalline form in the treatment of cancers, such as germline BRCA-mutated (gBRCAm) advanced ovarian cancer. | 2019-08-01 |
20190233401 | BIOCIDAL COATINGS AND METHODS FOR MAKING SAME - Methods for increasing biocidal activity of a substrate are provided. The methods can include attaching one or more ionic compounds to the substrate. The ionic compound can include a cationic moiety and at least one of an N-halamine precursor group or an N-halamine moiety. | 2019-08-01 |
20190233402 | COMPOUNDS - The invention relates to compounds of general formula (I): wherein R | 2019-08-01 |
20190233403 | POLYMORPHIC FORMS OF KINASE INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, PREPARATION METHOD THEREFOR AND USE THEREOF - The invention discloses polymorphic forms of a compound of formula I, pharmaceutical compositions containing same, preparation method therefor and use thereof. The compound of formula I of the present invention is as shown in formula I, of which the crystalline form can be crystalline form 1, crystalline form 2, crystalline form 3, crystalline form 5, crystalline form 6 or crystalline form 7. All the crystalline forms of the compound of formula I in the present invention have good crystalline stability and chemical stability and a decrease in purity of their main ingredient less than 2%. The preparation method of the present invention may be used to produce the various crystalline forms of the compound of formula I with high purity, and suitable for large scale production. | 2019-08-01 |
20190233404 | COMPOSITIONS AND METHODS FOR NEURAMINIDASE DETECTION AND QUANTITIFICATION - Provided herein are compounds having the structure of Formulas A-D and compositions thereof for use in the detection and quantification of viral neuraminidase. In particular, the compounds may be useful for the evaluation of viral strains and for vaccine evaluation. | 2019-08-01 |
20190233405 | PHENYLATE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USES THEREOF - The present invention discloses a phenylate derivative, a preparation method therefor, and a pharmaceutical composition and uses thereof. Specifically, the invention relates to phenylate derivatives represented by formula (I), a pharmaceutically-acceptable salt thereof, a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition containing the one or more compounds, and uses of the compounds in treating diseases related to PD-1/PD-L1 signal channels, such as cancers, infectious diseases and autoimmune diseases. | 2019-08-01 |
20190233406 | HYDROXYALKYLAMINE- and HYDROXYCYCLOALKYLAMINE-SUBSTITUTED DIAMINE-ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS - Disclosed are compounds of Formula A, or a salt thereof: | 2019-08-01 |
20190233407 | MONOCYCLIC BETA-LACTAM-SIDEROPHORE CONJUGATE, AND PREPARATION METHOD AND USE THEREOF - The present disclosure relates to the field of pharmaceutical synthesis, and more particularly, relates to a monocyclic β-lactam-siderophore conjugate as well as a method for synthesizing same and its use in the treatment of bacterial infectious diseases. Provided are a monocyclic β-lactam-siderophore conjugate represented by formula (I) as described herein, an optical isomer thereof or a pharmaceutically acceptable salt thereof, and a method for synthesizing same, and a use thereof in treating bacterial infectious diseases. | 2019-08-01 |
20190233408 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS - The present disclosure relates to compounds and a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing the compounds, and processes for their preparation. The disclosure also relates to the use of the compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor. | 2019-08-01 |
20190233409 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF - The present invention relates to compound of the formula 1.2, or a pharmaceutically acceptable salt, or hydrate thereof | 2019-08-01 |
20190233410 | ORGANOGEL BASED ON MOLECULES DERIVED FROM 7,7'-DIAZAISOINDIGO - The invention relates to: a compound derived from 7,7′-diazaisoindigo; an organogel, formed by these compounds, having an aggregation-induced emission (AIE) in the red region of the visible spectrum (600-800 nm); and a xerogel produced by drying said organogel. Due to these properties, said organogel or xerogel can be applied to optoelectronic devices or fluorescent sensors. | 2019-08-01 |
20190233411 | GCN2 INHIBITORS AND USES THEREOF - The present invention provides compounds, compositions thereof, and methods of using the same. | 2019-08-01 |
20190233412 | COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES - The present disclosure relates to compounds capable of emitting delayed fluorescence and uses of these compounds in organic light-emitting diodes. | 2019-08-01 |
20190233413 | CHEMICAL COMPOUNDS - The specification relates to compounds of Formula (I): | 2019-08-01 |
20190233414 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF - The invention provides novel chemical compounds useful for treating cancer, or a related disease or disorder thereof, and pharmaceutical composition and methods of preparation and use thereof. | 2019-08-01 |
20190233415 | N-{3-[3-CYCLOPROPYL-5-(2-FLUORO-4-IODOPHENYLAMINO)-6,8-DIMETHYL-2,4,7-TRIO- XO-3,4,6,7-TETRAHYDRO-2H-PYRIDO[4,3-D]PYRIMIDIN-1-YL]-PHENYL}-CYCLOPROPANE- CARBOXAMIDE DIMETHYL SULFOXIDE SOLVATE AS AN MEK1/2 INHIBITOR - Novel MEK1, MEK2 and MEK1/2 inhibitors which have lower toxicity in long-term dosage, including the novel compound N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6, 8-dimethyl-2,4,7-trioxo-3,4,6, 7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]-phenyl}-cyclopropanecarboxamide dimethyl sulfoxide solvate according to formula 1: | 2019-08-01 |
20190233416 | POLYMORPHIC FORMS OF VENETOCLAX - The present disclosure relates to crystalline forms of venetoclax and process for their preparation. The present disclosure also relates to process for preparation of amorphous venetoclax. | 2019-08-01 |
20190233417 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF - Imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof are useful as BTK inhibitors. | 2019-08-01 |
20190233418 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS - Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds. | 2019-08-01 |
20190233419 | POLYCYCLIC COMPOUNDS AND USES THEREOF - The present invention provides novel neuromodulatory compounds and compositions thereof The invention also relates to methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; as well as intermediates for the preparation compounds. | 2019-08-01 |
20190233420 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS - The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L | 2019-08-01 |
20190233421 | Process for Preparing Beta-Lactamase Inhibitor Hydroxylurea Intermediates - The present invention relates to processes for the preparation of N-protected (2S,5R)-6-hydroxy-7-oxo-N-piperidin-4-yl-1,6-diazabicyclo[3.2.1]octane-2-carboxamide intermediates. Such compounds have application in the preparation of beta-lactamase inhibitors such as 7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamides and esters, in particular, the beta lactamase inhibitor, (2S,5R)-7-oxo-N-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide. The present invention also encompasses intermediates useful in the disclosed processes and methods for their preparation. | 2019-08-01 |
20190233422 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM - Generally, the present invention provides novel quinolone compounds and pharmaceutical composition thereof which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing such compounds and compositions, and methods of making and using the same. | 2019-08-01 |
20190233423 | POLYMORPHS - The invention relates to polymorphous crystal modifications of a DPP-IV inhibitor, the preparation thereof and the use thereof for preparing a medicament. | 2019-08-01 |
20190233424 | INHIBITORS OF CELLULAR METABOLIC PROCESSES - The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA): | 2019-08-01 |
20190233425 | GCN2 INHIBITORS AND USES THEREOF - The present invention provides compounds, compositions thereof, and methods of using the same. | 2019-08-01 |
20190233426 | IMIDAZOLEPYRIDINE COMPOUNDS AND USES THEREOF - A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: | 2019-08-01 |
20190233427 | BICYCLIC HETEROARYL DERIVATIVES - The present invention relates to a compound of formula (I), wherein R | 2019-08-01 |
20190233428 | POLYMORPHS OF RUCAPARIB CAMSYLATE AND METHODS OF MAKING SAME - Novel polymorphs of rucaparib camsylate include Form alpha having XRPD peaks at diffraction angles (2θ) of 6.14±0.2, 12.41±0.2, 15.34±0.2, 15.95±0.2, 16.36±0.2, 16.51±0.2 and 19.67±0.2, Form beta having XRPD peaks at diffraction angles (2θ) of 6.86±0.2, 9.58±0.2, 12.75±0.2, 14.56±0.2, 15.05±0.2, 20.76±0.2 and 22.45±0.2, and Form gamma having XRPD peaks at diffraction angles (2θ) of 9.5±0.2, 12.73±0.2, 14.77±0.2, 15.16±0.2, 20.62±0.2, 22.33±0.2, 22.63±0.2 and 27.29±0.2. Methods are disclosed for the preparation of such polymorphic forms and pharmaceutical compositions containing such polymorphic forms. A method is disclosed for preparing a highly pure Form B of rucaparib camsylate. Pharmaceutical compositions containing highly pure Form B prepared by the method are disclosed. | 2019-08-01 |
20190233429 | CONFORMATIONALLY-CONSTRAINED BIOISOSTERES OF CAFFEIC ACID, AND SYNTHESIS AND THERAPEUTIC USES - A method of treating a disease condition in a mammal comprising administering a pharmacologically effective amount of a therapeutic, wherein the therapeutic includes a bioisosteres of caffeic acid. A pharmaceutical composition for treating a disease condition in a mammal comprising a first therapeutic that includes a bioisosteres of caffeic acid, wherein the condition may be breast cancer, and the pharmaceutical composition may include a second therapeutic for the disease condition that is not a bioisosteres of caffeic acid. | 2019-08-01 |
20190233430 | THAILANSTATIN ANALOGS - The invention provides novel cytotoxic compounds and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this invention relates to novel thailanstatin A analogs, useful as cytotoxic small molecule toxins in antibody-drug conjugates (ADCs). The present invention further relates to compositions including these cytotoxic compounds and ADCs, and methods for using these toxins and ADCs to treat pathological conditions including cancer. | 2019-08-01 |
20190233431 | THIENO-PYRIMIDINE DERIVATIVES AND USES THEREOF - Compounds having the general formula I or III, and pharmaceutical compositions comprising the same. The compounds of the present invention are useful as selective mutant epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitor, and for the treatment of EGFR related diseases and disorders such as cancer. | 2019-08-01 |
20190233432 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE - The present invention discloses a compound comprising the formula: | 2019-08-01 |
20190233433 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE - The description relates to imide-based compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type. | 2019-08-01 |
20190233434 | DIHYDROPYRAZOLE AZEPINE COMPOUND SERVING AS AKT INHIBITOR - Provided is a dihydropyrazole azepine compound serving as an Akt inhibitor; specifically disclosed is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof. | 2019-08-01 |
20190233435 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS - The present disclosure relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer. | 2019-08-01 |
20190233436 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - The present invention provides a compound useful as an agent for the prophylaxis or treatment of neurodegenerative disease and the like, or a salt thereof. | 2019-08-01 |
20190233437 | DIARYL MACROCYCLE POLYMORPH - This disclosure relates to polymorphs of (7S,13R)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one that are useful in the treatment of disease, such as cancer, in mammals. This disclosure also relates to compositions including such polymorphs, and to methods of using such compositions in the treatment of diseases, such as cancer, in mammals, especially in humans. | 2019-08-01 |
20190233438 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND - Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. | 2019-08-01 |
20190233439 | HISTONE DEACETYLASE INHIBITORS - This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3). | 2019-08-01 |
20190233440 | Substituted Quinazoline and Pyridopyrimidine Derivatives Useful as Anticancer Agents - Compounds of the general formula: | 2019-08-01 |
20190233441 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF - Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein. | 2019-08-01 |
20190233442 | SELECTIVE ESTROGEN RECEPTOR DOWN-REGULATORS (SERDS) - The present disclosure relates to orally bioavailable selective estrogen receptor down-regulators (SERDs) and the synthesis of the same. Further, the present disclosure teaches the utilization of the orally bioavailable selective estrogen receptor down-regulators (SERDs) in a treatment for proliferative diseases, including cancer, particularly breast cancer, and especially ER+ breast cancer. | 2019-08-01 |
20190233443 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF - Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, β-lactamase inhibitors (BLIs). | 2019-08-01 |
20190233444 | TRISUBSTITUTEDSILYLPHENOXYHETEROCYCLES AND ANALOGUES - The present disclosure relates to fungicidal active compounds, more specifically to trisubstitutedsilylphenoxyhetero-cycles and analogues thereof, processes and, intermediates for their preparation and use thereof as fungicidal active compound, particularly in the form of fungicide compositions. The present disclosure also relates to methods for the control of phytopathogenic fungi of plants using these compounds or compositions comprising thereof. | 2019-08-01 |
20190233445 | PROCESS FOR PREPARING TRIS[3-(ALKYLDIALKOXYSILYL)PROPYL]ISOCYANURATES - A process can prepare an isocyanurate compound by hydrosilylation. The compound is a tris[3-(trialkoxysilyl)propyl] isocyanurate, a tris[3-(alkyldialkoxysilyl)propyl] isocyanurate, and/or a tris[3-(dialkylalkoxysilyl)propyl] isocyanurate, The process includes (A) preparing a mixture of at least one carboxylic acid, a platinum catalyst, and 1,3,5-triallyl-1,3,5-triazine-2,4,6(1H,3H,5H)-trione; (B) heating the mixture to a temperature in the range of 40 to 140° C.; (C) adding at least one H-silane among a hydrotrialkoxysilane, a hydroalkyldialkoxysilane, and a hydrodialkylalkoxysilane to the mixture; (D) adding at least one alcohol to the mixture prepared in step (C); and (E) isolating the isocyanurate compound. | 2019-08-01 |
20190233446 | Organoamino-Functionalized Cyclic Oligosiloxanes for Deposition of Silicon-Containing Films - Organoamino-functionalized cyclic oligosiloxanes, which have at least two silicon and two oxygen atoms as well as an organoamino group and methods for making the organoamino-functionalized cyclic oligosiloxanes are disclosed. Methods for depositing silicon and oxygen containing films using the organoamino-functionalized cyclic oligosiloxanes are also disclosed. | 2019-08-01 |
20190233447 | PROTEIN PROXIMITY ASSAY IN FORMALIN FIXED PARAFFIN EMBEDDED TISSUE USING CAGED HAPTENS - Disclosed herein are caged haptens and caged hapten-antibody conjugates useful for enabling the detection of targets located proximally to each other in a sample. | 2019-08-01 |
20190233448 | CRYSTALLINE FORMS OF TENOFOVIR ALAFENAMIDE - The present invention relates to novel crystalline forms of salts and/or co-crystals of tenofovir alafenamide, the pharmaceutical formulations, and the therapeutic uses thereof in treating viral infections. | 2019-08-01 |
20190233449 | GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME - A compound, enantiomer, prodrug, diastereomer, or salt is provided which is an activator of the enzyme glucokinase and thus is believed to be useful in as treating diabetes and related diseases, which compound has the structure (I). A method for treating diabetes and related disease employing the compound, enantiomer, prodrug, diastereomer, or salt is also provided. | 2019-08-01 |
20190233450 | CHELATE COMPOUNDS - The invention provides compounds suitable for use as contrast agents in magnetic resonance imaging (MRI). The compounds of the present invention are manganese (II) complexes having advantageous properties as compared with similar known compounds. | 2019-08-01 |
20190233451 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - A compound including a first ligand L | 2019-08-01 |